ArticleAlimentary pharmacology & therapeutics2021
Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.
Article in Alimentary pharmacology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD.BMC public health · 2025Pooled it
- Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review.Journal of molecular medicine (Berlin, Germany) · 2024Pooled it
- Association between high-risk metabolic dysfunction-associated steatohepatitis and ischemic heart disease: a nationally representative study.Nutrition journal · 2026Article
- Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes.Diabetes, obesity & metabolism · 2025Article
- Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.Cardiovascular diabetology · 2025Observational
- Association Between Noninvasive Liver Fibrosis Scores and Heart Failure in a General Population.Journal of the American Heart Association · 2024Article
- Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.Scientific reports · 2024Article
- Molecular Imaging of Fibroblast Activation in Rabbit Atherosclerotic Plaques: a Preclinical PET/CT Study.Molecular imaging and biology · 2024Article
- Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.Research square · 2024Article
- Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.Cardiovascular diabetology · 2024Observational
- MR Elastography: Practical Questions, From theAJR. American journal of roentgenology · 2024Review
- Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD.Alimentary pharmacology & therapeutics · 2023Article
- Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.Hepatology international · 2023Article
- Performance of the Pooled Cohort Equations in non-alcoholic fatty liver disease: The Multi-Ethnic Study of Atherosclerosis.Liver international : official journal of the International Association for the Study of the Liver · 2023Article
- Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.Medicina (Kaunas, Lithuania) · 2023Article
- Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease.PloS one · 2023Article
- Shared Mechanisms between Cardiovascular Disease and NAFLD.Seminars in liver disease · 2022Review
- Magnetic resonance elastography: from invention to standard of care.Abdominal radiology (New York) · 2022Review
- The predictive value of revised diastolic dysfunction in outcomes of liver transplantation: A propensity score matching analysis.Frontiers in surgery · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundMagnetic resonance elastography (MRE) is a reliable non-invasive alternative to liver biopsy for assessing liver fibrosis. There are limited data regarding an association between liver fibrosis by MRE and risk of cardiovascular disease (CVD).
aimTo investigate the association of high-risk CVD phenotype determined by coronary artery calcification (CAC) with liver fibrosis by MRE in patients with non-alcoholic fatty liver disease (NAFLD).
methodThis was a cross-sectional analysis of well-characterised, prospective cohorts including 105 patients with NAFLD (MR imaging-derived proton density fat fraction ≥ 5%) with contemporaneous cardiac computed tomography (CT) and MRE. Patients were assessed using MRE for liver stiffness, and cardiac CT for the presence of CAC (defined as coronary artery calcium score > 0). Odds of presence of CAC were analysed using logistic regression analysis.
resultsThe average age and body mass index were 54.9 years and 32.9 kg/m
conclusionLiver stiffness determined by MRE is an independent predictor for the presence of CAC in patients with NAFLD. Patients with NAFLD and significant fibrosis by MRE should be considered for further cardiovascular risk assessment, regardless of their FRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.